In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster ...

Mercalis and PharmaCord announced the completion of their merger. The new company is rebranding itself as Valeris, which will ...

Pharmaceutical Executive: What are the factors that are impacting the compounded semaglutide market? Ferrin Williams, PharmD: ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...